

**Department of Planning and Budget
2014 Fiscal Impact Statement**

1. Bill Number: HB 874

House of Origin Introduced Substitute Engrossed
Second House In Committee Substitute Enrolled

2. Patron: Yost, Joseph R.

3. Committee: Health, Welfare and Institutions

4. Title: Designation and reporting of drugs of concern

5. Summary: The proposed legislation authorizes the Board of Pharmacy to identify “drugs of concern” and requires prescribers to report prescription drugs of concern to the Prescription Monitoring Program.

6. Budget Amendment Necessary: No. There is no clear estimate as to the additional expenditure required by this legislation. However, the need for additional nongeneral fund appropriation is not expected to be significant and can be covered within the agency’s existing appropriation.

7. Fiscal Impact is Indeterminate: See Item 8

8. Fiscal Implications: The proposal would require the promulgation of regulations by the Board of Pharmacy to identify a “drug of concern” as a covered substance thereby making it subject to reporting to the Prescription Monitoring Program (PMP). Since the “drug of concern” would not be a schedule II – IV drug and routinely reported by dispensers, there would be a cost relating to communicating such a requirement for reporting to pharmacies and notification to prescribers that the “drug of concern” would be included in the PMP. There would also be some additional cost for alteration of the database of the PMP to capture that information. Costs to PMP and to the Board of Pharmacy would depend on how often a “drug of concern” was added and the method used for communicating with prescribers and dispensers.

Since it is unknown as to how many “drugs of concern” would be identified; the fiscal impact on the agency cannot be determined. PMP is funded with federal and endowment funds without any support from regulatory fee revenue. It is estimated that there are sufficient funds to cover any PMP related costs associated with this bill. It is further estimated that the Board of Pharmacy would have revenue sufficient to cover any increased costs.

9. Specific Agency or Political Subdivisions Affected: Department of Health Professions

10. Technical Amendment Necessary: No

11. Other Comments: None

Date: 1/10/14